The Eye Machine Announces the Addition of Dr. Mike Samuel, Chief Medical Director of the Retina Institute to Advisory Board

Online PR News “13-August-2014“ The Eye Machine, LLC (TEM) is pleased to announce the addition of Dr. Mike Samuel, Chief Medical Director of the Retina Institute, to their Advisory Board. Dr. Samuel is considered the country’s leading expert in treating patients with Macular Degeneration, along with a variety of other eye diseases. Through the Retina Institute of California his practice treats thousands of patients every year suffering from both dry and wet age related macular degeneration (AMD). There is currently no approved treatment on the market for dry AMD. If left untreated dry AMD can progress to wet AMD and is the leading cause of blindness in patients over sixty years of age.

The Eye Machine is developing an innovative, non-invasive treatment for both dry and wet AMD. TEMs treatment involves using electrophoresis to help stimulate proper blood, nutrient, and ATP enzyme delivery to the macula, located in the center of the retina. In previous studies conducted this treatment has been shown to improve patient vision by an average of 61% by temporarily reversing the effects of the disease and has shown the ability to stop the progression of it. The current approved treatments for wet AMD consist of highly invasive laser surgery and injections into the cornea, which often results in varying side effects. Upon FDA approval TEM’s medical device will provide the first non-invasive treatment for all AMD patients.

The newly established relationship with Dr. Samuel will allow TEM to have their clinical trials conducted at the Retina Institute, along with a network of retinologists in both Phoenix and Boston introduced to the company by the institute.

Dr. George O’Clock, Chief Science Advisor and inventor of the medical device, expressed his excitement for the new partnership, We are extremely pleased to have Dr. Mike Samuel join our team as we begin our clinical trials. His extensive experience as a renowned clinician having conducted 125 clinical trials with the Retina Institute will surely aid us tremendously in gaining the approvals we need and in conducting an aggressive product launch. We appreciate his foresight and will benefit greatly from his addition to the Company.

About Dr. Mike Samuel:

Best Doctors in the USA

Dr. Samuel is a nationally renowned clinician, surgeon and researcher. Along with Dr. Chang, Founder of The Retina Institute, Dr. Samuel was part of the team that performed the world’s first surgical implantation of stem cell treatment for dry macular degeneration, which was in collaboration with the Johnson & Johnson Stem Cell organization.
Dr. Samuel has published over 25 peer-reviewed research articles, a number of book chapters for medical text, and is a section editor for the Retina Times Magazine, a publication of the American Society of Retinal Specialists. He has also authored the leading book, Macular Degeneration: A Complete Guide for Patients and Their Families. Dr. Samuel specializes in the diagnosis and treatment of various retinal diseases, including diabetic retinopathy, age-related macular degeneration, macular hole, epiretinal membrane, and retinal vascular diseases. He is certified by the American Board of Ophthalmology and is a member of the American Academy of Ophthalmology, American Medical Association, and the American Society of Retinal Specialists.

He is consistently named as one of the Best Doctors in the USA and has won numerous surgical teaching awards. He also serves as the chairman of the executive committee of the Retina Institute of California as well as the Chief Scientific Officer of the California Center for Clinical Research.

For a complete bio please visit: http://retina2020.com/surgeon/michael-samuel-md/

About The Eye Machine:

The Eye Machine, LLC was formed to develop, manufacture, and lease to medical professionals, primarily optometrists, a medical device to treat macular degeneration by delivering low level electric current (microcurrent) to the eye, mitigating the effects of age-related macular degeneration and diabetic retinopathy.

The Eye Machines BioCurrent Therapy represents a new, non-invasive treatment for all forms of macular degeneration. The BioCurrent ranges have very specific frequencies to stimulate the desired physiologic response at the retinal level. This low current has been shown by studies to stimulate the production of the active transport enzyme, adenosine triphosphate (ATP), which facilitates the movement of nutrition from the blood to the cell. According to recent studies, it improves permeability of the blood vessel membranes and cells, allows better oxygen and nutrition delivery to the cells, metabolism, and removal of by-products from the cells. Through these mechanisms, BioCurrent therapy improves retinal pigment epithelium (RPE) efficiency and in so doing may restore and/or improve retinal function.

For more information please visit www.theeyemachine.com or call Investor Relations at: 760-565-1760

Media Information
Lance Eldred
lana@theeyemachine.com
http://www.theeyemachine.com